|
06 Oct 2021 |
Precirix Dosed First Patients in Phase I/II Clinical Study Evaluating CAM-H2 in HER2-Positive Metastatic Cancer
|
|
06 Oct 2021 |
Masked Antibodies and Cytokines as Prodrugs: strongly emerging novel technologies providing plenty of opportunities for founders, investors and partnerships
|
|
05 Oct 2021 |
Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors
|
|
05 Oct 2021 |
AZD7442 request for Emergency Use Authorization for COVID-19 prophylaxis filed in US
|
|
04 Oct 2021 |
AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular Psoriasis
|
|
04 Oct 2021 |
Himalaya Therapeutics Announces Submission in Mainland China of IND Applications for its CAB-AXL-ADC to treat sarcomas and NSCLC, its CAB-ROR2-ADC to treat melanoma and NSCLC
|
|
04 Oct 2021 |
Compugen Announces Milestone Payment from AstraZeneca Triggered by First Patient Dosed with TIGIT Bispecific Derived from COM902
|
|
04 Oct 2021 |
Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
|
|
04 Oct 2021 |
Kyowa Kirin and Amgen Present Positive Late-Breaking Data from Phase 2 Study of KHK4083/AMG 451 in Adult Patients with Moderate-to-Severe Atopic Dermatitis at EADV Congress
|
|
04 Oct 2021 |
Polpharma Biologics Group Announces that the Biologics License Application (BLA) Submitted by its Joint Venture Bioeq for its Biosimilar Ranibizumab has Been Accepted for Review by the U.S. Food and Drug Administration (FDA)
|
|
04 Oct 2021 |
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Granted Breakthrough Therapy Designation in US for Patients with HER2-Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens
|
|
04 Oct 2021 |
SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19
|
|
04 Oct 2021 |
Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies
|
|
04 Oct 2021 |
Ambrx Announces Positive Data on ARX788 for the Treatment of HER2+ Gastric Cancer Presented at CSCO
|
|
01 Oct 2021 |
European Medicines Agency Validates Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as First-Line Treatment for Patients with Unresectable or Metastatic Melanoma
|
|
01 Oct 2021 |
Alligator Bioscience Announces First Patient Dosed in OPTIMIZE-1 Phase II Clinical Trial Evaluating Mitazalimab in Combination with mFOLFIRINOX for the Treatment of Pancreatic Cancer
|
|
01 Oct 2021 |
Merck KGaA, Darmstadt, Germany Announces Mutual Decision to End Bintrafusp Alfa Agreement with GSK
|
|
30 Sep 2021 |
Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals
|
|
30 Sep 2021 |
Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in Phase 1 Expansion Trial of SIRPα Antagonist Monoclonal Antibody BI 765063 in combination with anti-PD-1 Antibody Ezabenlimab...
|
|
30 Sep 2021 |
New REGEN-COV™ (casirivimab and imdevimab) Data Show Supportive Results in Patients Hospitalized with COVID-19
|
|
29 Sep 2021 |
FDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy
|
|
28 Sep 2021 |
FDA Accepts Libtayo® (cemiplimab-rwlc) for Priority Review for Advanced Cervical Cancer
|
|
28 Sep 2021 |
Eisai Initiates Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer's Disease Under the Accelerated Approval Pathway
|
|
27 Sep 2021 |
Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase III Trial in Patients with Generalized Myasthenia Gravis
|
|
27 Sep 2021 |
ADC Therapeutics Doses First Patient in Phase 1 Clinical Trial of ADCT-901 in Advanced Solid Tumors
|
